Brief: Bluejay Reports FDA Agrees To Consider Its Plan To Pursue A De Novo Regulatory Pathway For The Symphony Il-6 Test
09/06/2022 14:54
June 9 (Reuters) - Bluejay Diagnostics Inc BJDX.O :
* BLUEJAY REPORTS FDA AGREES TO CONSIDER ITS PLAN TO PURSUE
A DE
NOVO REGULATORY PATHWAY FOR THE SYMPHONY IL-6 TEST
* BLUEJAY DIAGNOSTICS INC - FDA STATED THAT BLUEJAY'S
SYMPHONY
IL-6 TEST COULD BE CONSIDERED FOR DE NOVO PATHWAY
Source text for Eikon: ID:nGNX9zFFSZ
Further company coverage: BJDX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Bluejay Diagnostics
See all newsBrief: Bluejay Diagnostics Announces Successful Completion Of Enrollment In The Symon-II Multicenter Clinical Validation Study
Brief: Bluejay Diagnostics And Argonaut Manufacturing Services Announce Strategic Partnership
Bluejay Diagnostics Q1 net loss unchanged
Brief: Bluejay Diagnostics, Inc. Announces Completion Of 624 Patient Enrollments In Symon-Ii Pivotal Clinical Trial
Brief: Bluejay Diagnostics Provides Corporate Update And 2026 Strategic Outlook